Broadfin Capital’s Aegerion Pharmaceuticals AEGR Stock Holding History

Broadfin Capital’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-500,000	Closed	-$5.05M	–	92
2015 Q4	$5.05M	Buy	+500,000	New	+$6.02M	0.31%	65
2015 Q2	–	Sell	-50,000	Closed	-$1.31M	–	102
2015 Q1	$1.31M	Sell	50,000 -100,000	-67%	-$2.54M	0.1%	78
2014 Q4	$3.14M	Buy	+150,000	New	+$3.78M	0.27%	66

Broadfin Capital's AEGR Position: Q4 2016 in Review

Broadfin Capital sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 4,361,291 shares — an estimated $13M sold.

Broadfin Capital first reported a position in AEGR in Q1 2014 and held it in 11 quarters. The position peaked at $65.5M in Q1 2015. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

Broadfin Capital reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Broadfin Capital sold 4,361,291 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $13M.
Broadfin Capital first reported a position in Aegerion Pharmaceuticals in Q1 2014 and held it in 11 quarters.
Broadfin Capital's Aegerion Pharmaceuticals position peaked at $65.5M in Q1 2015.
0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Broadfin Capital's 13F filing for Q4 2016, filed 14 Feb 2017.